Kasey L. Couts

This study identifies immune evasion mechanisms in rare melanomas and shows that decitabine reactivates innate immune pathways, improving immune responsiveness.

This study examines serum oxylipin profiles in melanoma subtypes and immunotherapy responders to identify potential metabolic biomarkers for treatment response.

This study uses multi-omics factor analysis to identify molecular pathways linked to immunotherapy outcomes in melanoma, revealing associations between tumor transcriptomes, microbiomes, and clinical responses.